Back

Membrane-localised mutations predict the efficacy of cancer immunotherapy

2022-05-29 oncology Title + abstract only
View on medRxiv
Show abstract

Due to their genetic instability, tumor cells bear mutations that can effectively be recognized by the immune system. In the clinic, immune checkpoint immunotherapy (ICI) can re-activate immune reactions against mutated proteins, known as neoantigens, leading to remarkable remission in cancer patients. Nevertheless, only a minority of patients are responsive to ICI, and approaches for prediction of responsiveness remain elusive yet are needed to improve the success of cancer treatments. While th...

Predicted journal destinations